The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop virus-like particles (VLPs) as a delivery mechanism for therapeutic proteins to address the HIV/AIDS pandemic. The key objectives are to: 1) Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, then target the reactivated cells for elimination using adeno-associated virus...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research to characterize the HIV latent reservoir and understand the mechanisms driving its persistence in people living with HIV on antiretroviral therapy. The $234,115 award will support in-depth sequencing of intact and defective HIV proviruses to map the clonal distribution of infected cells, as well as...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance the understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The $285,816 award, spanning from September 2024 to October 2027, will fund research to identify global proteomic changes to ADPR during HIV-1 latency and reactivation, investigate PARP-HIV-1 interactions in...
This $220,224 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports computational research on the assembly, maturation, and uncoating processes of the HIV-1 virus. The University of Chicago, the grant recipient, will investigate factors beyond the viral capsid that influence critical morphological transitions in the HIV-1 life cycle, such as the role of host cell factors and...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting a study of acute HIV infection to investigate strategies for HIV eradication. The $794,045 award to The Regents of the University of California, San Francisco (UCSF) aims to identify host cellular mechanisms that drive HIV reservoir decay and sustained viral control, with the goal of informing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the role of the PCIF1 protein in regulating host-HIV interactions. The $502,861 award will support research to define the dynamics and mapping of human N6,2'-O-dimethyladenosine (m6Am) RNA methylation during HIV infection and methamphetamine exposure, determine how HIV alters the m6Am methylome of host...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at investigating the role of the protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The total funding amount is $775,391.00, with a project period from August 1, 2024 to June 30, 2029. The research team, led by investigators at Vitalant Research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $624,902 to The University of Texas Health Science Center at San Antonio (UTHSCSA) from April 2025 through March 2030. The grant will support research to characterize how the HIV accessory protein Vpr induces epigenetic remodeling in myeloid cells, and define Vpr's role in HIV persistence. The goals are to: 1)...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,081,920.00 to the University of Florida to investigate the role of a unique family of transcription factors in regulating HIV transcription and latency. The key objectives are to:
Screen a library of small hairpin RNAs targeting 31 pioneer transcription factors to identify novel regulators of HIV transcription in cell line models.
Validate the activity of identified hits in cell line and primary CD4+ T cell models, evaluating their impact on HIV transcription, CD4+ T cell function, and dependence on the viral Tat protein.
Comprehensively characterize the transcriptional regulatory mechanisms of the 3 most promising pioneer factor hits, including their recruitment to HIV and cellular promoters, modulation of HIV chromatin structure, and transcriptional regulation.
The overall goal is to uncover new host transcriptional regulators that could be leveraged for HIV cure strategies or diagnostic purposes. The award period runs from July 1, 2024 to May 31, 2026.